Baxter’s New Vivia Home HD Machine is (Almost) Here!
Baxter presented human studies data at the ERA-EDTA Congress in Amsterdam this June supporting the safety and efficacy of the new Vivia home dialysis system. With four treatments per week for 10 weeks, averaging 3.8 hours per treatment, the mean weekly Kt/V of the 22 US patients was 2.97, with no serious adverse events related to the machine. A small nocturnal trial was also done in Canada.
Read the full article » | Posted 07-03-2014
Related Articles
- The Lancet Digital Health published results of Humacyte’s Phase III clinical trial of its V007 acellular tissue engineered vessel (ATEV) HD access Posted 09-18-2026
- Humacyte, Inc. announced Robert J. Kossman, MD, FACP, FASN and Prabir Roy-Chaudhury, MD, PhD, FASN have joined the company as advisors. Posted 08-21-2026
- Byonyks on the Move: X-2 and X-3 APD Devices in Development Posted 07-16-2026
- Dr. Ben Reynolds and the Virtual Reality Kidney Dialysis Training Project Posted 06-17-2026